A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.

ABSTRACT:

Objective

To provide data on the short-term effect of intravitreal bevacizumab for diabetic macular edema (DME).

Design

Randomized phase II clinical trial.

Participants

One hundred twenty-one eyes of 121 subjects (109 eligible for analysis) with DME and Snellen acuity equivalent ranging from 20/32 to 20/320.

Interventions

Random assignment to 1 of 5 groups: (A) focal photocoagulation at baseline (n = 19), (B) intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks (n = 22), (C) intravitreal injection of 2.5 mg of bevacizumab at baseline and 6 weeks (n = 24), (D) intravitreal injection of 1.25 mg of bevacizumab at baseline and sham injection at 6 weeks (n = 22), or (E) intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks with

SUBMITTER: Diabetic Retinopathy Clinical Research Network 

PROVIDER: S-EPMC2245885 | biostudies-literature | 2007 Oct

REPOSITORIES: biostudies-literature